The efficacy of trastuzumab deruxtecan in Chinese breast cancer patients: a real-world multicenter study

During a 8-month follow-up period, the disease control rate for patients with HER-positive breast cancer was 88.89% (16/18). The disease control rate for patients with HER-2 low-expressing breast cancer was 85.71% (6/7). The most common adverse reactions were gastrointestinal reactions, such as nausea, which occurred in 64.00% (16/25), and interstitial lung disease, which had a probability of occurring in 4.00% (1/25). In this real-world study, trastuzumab deruxtecan showed favorable efficacy and safety in both HER-2-positive breast cancer and HER-2 low-expressing breast cancer.